Iranian Society of Gynecology Oncology


Gynecologist Oncologist, Associate Professor, Department of Gynecology Oncology, Valiasr Hospital, Tehran University of Medical Sciences, Tehran, Iran


  1. Taylor HS, Manson JE. Update in hormone therapy use in menopause. J Clin Endocrinol Metab. 2011;96(2):255-64. [DOI:10.1210/jc.2010-0536]
  2. North American Menopause Society . The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012;19(3):257-71. [DOI:10.1097/gme.0b013e31824b970a]
  3. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-68. [DOI:10.1001/jama.2013.278040]
  4. Chlebowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, Stefanick ML, et al. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. JAMA Oncol. 2015;1(3):296-305. [DOI:10.1001/jamaoncol.2015.0494]
  5. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al. Postmenopausal hormone therapy: an Endocrine Society scientiļ¬c statement. J Clin Endocrinol Metab. 2010;95(7 Suppl 1):s1-s66. [DOI:10.1210/jc.2009-2509]
  6. Ibeanu O, Modesitt SC, Ducie J, von Gruenigen V, Agueh M, Fader AN. Hormone replacement therapy in gynecologic cancer survivors: why not?. Gynecol Oncol. 2011;122(2):447-54. [DOI:10.1016/j.ygyno.2011.03.012]